Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity

Chia Siang Kow; Syed Shahzad Hasan

doi:10.1093/eurjpc/zwaa086

Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity

Chia Siang Kow, Syed Shahzad Hasan

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Abstract

Aimo et al.1 presented an elegant review of the antiviral mechanism of amiodarone, which is a commonly used antiarrhythmic drug. Although in vitro experiments demonstrated the ability of amiodarone to inhibit coronavirus, we are still wary of the authors’ recommendation to evaluate amiodarone for the treatment of coronavirus disease 2019 (COVID-19) in clinical trials.

Original language	English
Pages (from-to)	e52
Number of pages	1
Journal	European Journal of Preventive Cardiology
Volume	28
Issue number	18
Early online date	12 Nov 2020
DOIs	https://doi.org/10.1093/eurjpc/zwaa086
Publication status	Published - 9 Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/eurjpc/zwaa086Licence: Unspecified

Cite this

@article{9a406f25e4334104ae3cfa463365dd88,

title = "Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity",

abstract = "Aimo et al.1 presented an elegant review of the antiviral mechanism of amiodarone, which is a commonly used antiarrhythmic drug. Although in vitro experiments demonstrated the ability of amiodarone to inhibit coronavirus, we are still wary of the authors{\textquoteright} recommendation to evaluate amiodarone for the treatment of coronavirus disease 2019 (COVID-19) in clinical trials.",

keywords = "amiodarone, pulmonary toxicity, COVID-19",

author = "Kow, {Chia Siang} and Hasan, {Syed Shahzad}",

year = "2022",

month = feb,

day = "9",

doi = "10.1093/eurjpc/zwaa086",

language = "English",

volume = "28",

pages = "e52",

journal = "European Journal of Cardiovascular Prevention and Rehabilitation",

issn = "2047-4873",

publisher = "SAGE Publications Ltd",

number = "18",

}

TY - JOUR

T1 - Amiodarone in COVID-19

T2 - let's not forget its potential for pulmonary toxicity

AU - Kow, Chia Siang

AU - Hasan, Syed Shahzad

PY - 2022/2/9

Y1 - 2022/2/9

N2 - Aimo et al.1 presented an elegant review of the antiviral mechanism of amiodarone, which is a commonly used antiarrhythmic drug. Although in vitro experiments demonstrated the ability of amiodarone to inhibit coronavirus, we are still wary of the authors’ recommendation to evaluate amiodarone for the treatment of coronavirus disease 2019 (COVID-19) in clinical trials.

AB - Aimo et al.1 presented an elegant review of the antiviral mechanism of amiodarone, which is a commonly used antiarrhythmic drug. Although in vitro experiments demonstrated the ability of amiodarone to inhibit coronavirus, we are still wary of the authors’ recommendation to evaluate amiodarone for the treatment of coronavirus disease 2019 (COVID-19) in clinical trials.

KW - amiodarone

KW - pulmonary toxicity

KW - COVID-19

UR - http://www.scopus.com/inward/record.url?scp=85124442563&partnerID=8YFLogxK

U2 - 10.1093/eurjpc/zwaa086

DO - 10.1093/eurjpc/zwaa086

M3 - Letter

C2 - 33624070

VL - 28

SP - e52

JO - European Journal of Cardiovascular Prevention and Rehabilitation

JF - European Journal of Cardiovascular Prevention and Rehabilitation

SN - 2047-4873

IS - 18

ER -

Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this